FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142528698> ?p ?o ?g. }

• W3142528698 endingPage "S3" @default.
• W3142528698 startingPage "S3" @default.
• W3142528698 abstract "Abstract Background Human adenovirus (HAdV) viremia can cause significant morbidity among pediatric patients undergoing solid-organ transplantation (SOT). Currently, there are no US Food and Drug Administration (FDA)-approved treatments for HAdV infections, and historically the mainstay of treatment has been decreasing immunosuppression with antiviral therapies reserved for those with severe disease. Brincidofovir (BCV) is an investigational antiviral drug with potency against HAdV. We describe four cases of disseminated HAdV infection treated with (BCV) among pediatric SOT patients. Methods We retrospectively reviewed 4 cases of severe disseminated HAdV infection, which occurred between 2018 and 2019, in a tertiary pediatric transplant center. HAdV infection was defined as a positive HAdV PCR from a clinical specimen. Baseline clinical characteristics, disease course, treatment, and outcomes were reviewed. Results Four pediatric SOT patients (2 kidneys, 1 dual kidney/liver, and 1 liver) ranging in age from 9 months to 19 years were diagnosed with HAdV infection (Table 1). Patients presented with varied symptoms from 12 to 912 days post-transplant. Peak HAdV viral load ranged from 37,000 to &gt;1,000,000 copies/mL. All patients had disseminated disease with evidence of graft involvement and varying degrees of acute kidney injury (AKI) making them candidates for BCV therapy over cidofovir to avoid nephrotoxicity. Three out of four patients received cidofovir prior to conversion to BCV. IRB-approved compassionate use of BCV was dosed at 2 mg/kg (max 100 mg) twice weekly PO along with reduced immunosuppression. Resolution of symptoms and HAdV viremia was seen at a mean of 21.5 days (range 15–32) of therapy. All patients had resolution of AKI with a return to baseline creatinine after therapy. Conclusions Though HAdV infection in pediatric SOT patients is uncommon, a subset of patients experience severe disease, morbidity, and graft loss. Currently, HAdV is not routinely monitored in pediatric SOT transplant patients. Although supportive care and decreased immunosuppression remain as the most important component of therapy, BCV was well tolerated and efficacious in our series. Further research is needed to better understand risk factors for HAdV infection and potential antiviral treatment options to improve patient outcomes." @default.
• W3142528698 created "2021-04-13" @default.
• W3142528698 creator A5014613828 @default.
• W3142528698 creator A5019779858 @default.
• W3142528698 creator A5038127443 @default.
• W3142528698 creator A5042275952 @default.
• W3142528698 creator A5063797083 @default.
• W3142528698 creator A5063897872 @default.
• W3142528698 creator A5072945397 @default.
• W3142528698 creator A5083791464 @default.
• W3142528698 creator A5087801155 @default.
• W3142528698 date "2021-03-01" @default.
• W3142528698 modified "2023-10-14" @default.
• W3142528698 title "#18: Brincidofovir for the Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid-organ Transplant Recipients" @default.
• W3142528698 doi "https://doi.org/10.1093/jpids/piaa170.008" @default.
• W3142528698 hasPublicationYear "2021" @default.
• W3142528698 type Work @default.
• W3142528698 sameAs 3142528698 @default.
• W3142528698 citedByCount "1" @default.
• W3142528698 crossrefType "journal-article" @default.
• W3142528698 hasAuthorship W3142528698A5014613828 @default.
• W3142528698 hasAuthorship W3142528698A5019779858 @default.
• W3142528698 hasAuthorship W3142528698A5038127443 @default.
• W3142528698 hasAuthorship W3142528698A5042275952 @default.
• W3142528698 hasAuthorship W3142528698A5063797083 @default.
• W3142528698 hasAuthorship W3142528698A5063897872 @default.
• W3142528698 hasAuthorship W3142528698A5072945397 @default.
• W3142528698 hasAuthorship W3142528698A5083791464 @default.
• W3142528698 hasAuthorship W3142528698A5087801155 @default.
• W3142528698 hasBestOaLocation W31425286981 @default.
• W3142528698 hasConcept C126189478 @default.
• W3142528698 hasConcept C126322002 @default.
• W3142528698 hasConcept C142462285 @default.
• W3142528698 hasConcept C203014093 @default.
• W3142528698 hasConcept C2522874641 @default.
• W3142528698 hasConcept C2776185481 @default.
• W3142528698 hasConcept C2776824251 @default.
• W3142528698 hasConcept C2780091579 @default.
• W3142528698 hasConcept C2780252810 @default.
• W3142528698 hasConcept C2781036101 @default.
• W3142528698 hasConcept C2911091166 @default.
• W3142528698 hasConcept C71924100 @default.
• W3142528698 hasConcept C90924648 @default.
• W3142528698 hasConceptScore W3142528698C126189478 @default.
• W3142528698 hasConceptScore W3142528698C126322002 @default.
• W3142528698 hasConceptScore W3142528698C142462285 @default.
• W3142528698 hasConceptScore W3142528698C203014093 @default.
• W3142528698 hasConceptScore W3142528698C2522874641 @default.
• W3142528698 hasConceptScore W3142528698C2776185481 @default.
• W3142528698 hasConceptScore W3142528698C2776824251 @default.
• W3142528698 hasConceptScore W3142528698C2780091579 @default.
• W3142528698 hasConceptScore W3142528698C2780252810 @default.
• W3142528698 hasConceptScore W3142528698C2781036101 @default.
• W3142528698 hasConceptScore W3142528698C2911091166 @default.
• W3142528698 hasConceptScore W3142528698C71924100 @default.
• W3142528698 hasConceptScore W3142528698C90924648 @default.
• W3142528698 hasIssue "Supplement_1" @default.
• W3142528698 hasLocation W31425286981 @default.
• W3142528698 hasOpenAccess W3142528698 @default.
• W3142528698 hasPrimaryLocation W31425286981 @default.
• W3142528698 hasRelatedWork W2004766863 @default.
• W3142528698 hasRelatedWork W2083886748 @default.
• W3142528698 hasRelatedWork W2086209058 @default.
• W3142528698 hasRelatedWork W2564645074 @default.
• W3142528698 hasRelatedWork W2605509926 @default.
• W3142528698 hasRelatedWork W2771329708 @default.
• W3142528698 hasRelatedWork W2998605484 @default.
• W3142528698 hasRelatedWork W3199088592 @default.
• W3142528698 hasRelatedWork W4308611952 @default.
• W3142528698 hasRelatedWork W4386306103 @default.
• W3142528698 hasVolume "10" @default.
• W3142528698 isParatext "false" @default.
• W3142528698 isRetracted "false" @default.
• W3142528698 magId "3142528698" @default.
• W3142528698 workType "article" @default.